H.R. 384 · 118th Congress
Protecting Life from Chemical Abortions Act
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 118th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
R
HernSponsor40 cosponsors · 40 R
R
Aderholt
LB
R
Boebert
BB
R
Babin
JB
R
Banks
JB
R
Baird
AC
R
Clyde
BC
R
Cline
JD
R
Duncan
JE
R
Ellzey
RF
R
Feenstra
BF
R
Finstad
RF
R
Fry
PG
R
Gosar
GG
R
Grothman
MG
R
Green
MG
R
Guest
DH
R
Harshbarger
AH
R
Hinson
RJ
R
Jackson
TK
R
Kelly
DL
R
Lamborn
DL
R
LaMalfa
BL
R
Loudermilk
NL
R
Langworthy
JM
R
Moolenaar
BM
R
Mast
MM
R
Miller
AP
R
Pfluger
JR
R
Rutherford
JR
R
Rose
PS
R
Sessions
DW
R
Webster
RW
R
Weber
BW
R
Wenstrup
MB
R
Bost
BG
R
Good
KS
R
Self
RY
R
Yakym
DC
R
Crenshaw
DN
R
Newhouse34 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.)
What it does: CRS summary · Introduced in House · Jan 17, 2023
Protecting Life from Chemical Abortions Act
This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.)
The FDA regulates the use of mifepristone through the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program. The program requires health care providers to comply with certain requirements in order to prescribe or dispense mifepristone to end a pregnancy; the program previously included an in-person dispensing requirement that required mifepristone to be directly dispensed to patients in clinics, medical offices, or hospitals. During the COVID-19 public health emergency, the FDA temporarily stopped enforcing the in-person dispensing requirement, which allowed mail-order pharmacies to fill and dispense mifepristone prescriptions.
In January 2023, the FDA modified program requirements so as to (1) remove the in-person dispensing requirement, and (2) require pharmacies to be certified in the program in order to dispense mifepristone. The modifications allow retail pharmacies, after receiving certification, to dispense mifepristone pursuant to prescriptions that are written by program-certified prescribers.
The bill nullifies the January 2023 changes and prohibits the FDA from (1) exercising any enforcement discretion with respect to program requirements, or (2) reducing program protections until every state submits certain data regarding abortions to the Centers for Disease Control and Prevention.
The bill also generally prohibits the declaration of a public health emergency with respect to abortions.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Protecting Life from Chemical Abortions Act
Latest action (Jan 27, 2023): Referred to the Subcommittee on Health.
Policy area: Health · Origin: House · Introduced: Jan 17, 2023
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.